Arthritis news. Anytime. Anywhere.

Let BC PharmaCare hear “Your Voice” on sarilumab

Stickman with megaphone calling for Your Voice patient inputBC PharmaCare is looking for your input on sarilumab for the treatment of rheumatoid arthritis

Sarilumab (Kevzara™) is a fully human monoclonal antibody that targets IL-6, a protein central to the development of the signs and symptoms of rheumatoid arthritis. Sarilumab can be used alone or in combination with methotrexate or other traditional disease-modifying antirheumatic drugs (DMARDs). It is given by subcutaneous (under the skin) injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. 

You can give input if you are a B.C. resident and have rheumatoid arthritis, a caregiver to someone with rheumatoid arthritis, or if your group represents people who live with rheumatoid arthritis.

If you would like our help in providing your input, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient organization on your behalf. Please provide your input to us by Wednesday, March 8 so that we may submit the questionnaire in time for the deadline.

The submission deadline is midnight on March 15, 2017. Patients and caregivers may give their input directly through the links below.

Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:

  • To view the information sheet for sarilumab for rheumatoid arthritis: click here
  • For the Patient Questionnaire: click here
  • For the Caregiver Questionnaire: click here
  • For the Patient Group Questionnaire: click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)